Brainstorm cell therapeutics announces second quarter 2022 financial results and provides a corporate update

Brainstorm to submit a biologics license application (bla) to the u.s. food and drug administration (fda) for nurown ®  for the treatment of als new clinical analyses reinforce the conclusions from nurown's® phase 3 clinical trial conference call and webcast at 8:00 a.m. eastern time today new york , aug. 15, 2022 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the second quarter ended june 30, 2022, and provided a corporate update.
BCLI Ratings Summary
BCLI Quant Ranking